UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in Twist Bioscience Co. (NASDAQ:TWST) by 8.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 880,199 shares of the company’s stock after selling 81,038 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Twist Bioscience were worth $39,767,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Thrivent Financial for Lutherans bought a new position in shares of Twist Bioscience in the third quarter valued at approximately $43,992,000. Point72 Asset Management L.P. grew its stake in Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after purchasing an additional 613,057 shares during the period. Fred Alger Management LLC increased its position in shares of Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after purchasing an additional 575,080 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Twist Bioscience by 4,133.1% during the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after purchasing an additional 300,891 shares during the period. Finally, Farallon Capital Management LLC purchased a new position in shares of Twist Bioscience in the 2nd quarter worth about $9,462,000.

Twist Bioscience Stock Up 0.6 %

Shares of NASDAQ TWST opened at $50.61 on Wednesday. The business has a 50-day simple moving average of $44.02 and a two-hundred day simple moving average of $46.27. Twist Bioscience Co. has a 52 week low of $24.15 and a 52 week high of $60.90. The company has a market cap of $3.00 billion, a P/E ratio of -14.06 and a beta of 1.82.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Robert W. Baird upped their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. Evercore ISI raised their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Scotiabank upped their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. Finally, Barclays decreased their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $51.00.

Insider Activity

In related news, Director Robert Chess sold 3,600 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $47.26, for a total transaction of $170,136.00. Following the completion of the transaction, the director now directly owns 21,641 shares in the company, valued at $1,022,753.66. The trade was a 14.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Paula Green sold 3,310 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total value of $143,025.10. Following the completion of the transaction, the senior vice president now owns 84,585 shares in the company, valued at $3,654,917.85. This represents a 3.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 98,118 shares of company stock worth $4,391,151. 3.92% of the stock is owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.